Akero Therapeutics, Inc.
AKRO$1.57T
Mega CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSOUTH SAN FRANCISCO74 employees
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Apr 15, 2026
TomorrowMarket Overview
Stock performance and key metrics
AKRO News
Catalyst Timeline
1 upcoming, 0 past
Phase 3Next
Efruxifermin Phase 3 Results Expected
April 2026~EstimatedEfruxifermin700
Primary completion for Efruxifermin trial (NCT06161571) in NASH/MASH
SourceDrug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Efruxifermin | Phase 3 | NASH - Nonalcoholic Steatohepatitis | - | - |
EFX | Phase 2 | NASH - Nonalcoholic Steatohepatitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply